Cancer Genetics, Inc. (GCI) and the Mayo Clinic’s joint venture has formed Oncospire Genomics, based in Rochester, MN, to pursue the development of novel and unique next generation sequencing diagnostic panels in areas of critical need in oncology. Oncospire is equally owned by both parties and will initially pursue the development of NGS panels for lung cancer, multiple myeloma, and follicular lymphoma.   The multi-disciplinary approach will combine Mayo Clinic’s next generation sequencin...